Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
The 10th Anniversary of Vaccines—Cancer Vaccines and Immunotherapy
share announcement

The 10th Anniversary of Vaccines—Cancer Vaccines and Immunotherapy

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 6236

Special Issue Editor

Dr. Subbaya Subramanian

E-Mail Website
Guest Editor
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Interests: colorectal cancer; tumor immunology; T cells; immune cells; microbiome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In 2022, we will celebrate the 10th anniversary volume of the journal Vaccines (ISSN 2076-393X), and we would be thrilled if you could join us on this wonderful occasion.

Vaccines is an international, peer-reviewed, quick-refereeing, open access journal published online by MDPI, Basel, Switzerland. Vaccines is indexed by SCIE, PubMed (NLM), as well as others. The Impact Factor for this journal is 4.422, and it ranks 74/162 (Q2) in “Immunology” and 63/140 (Q2) in “Medicine, Research & Experimental Pharmacology” in Web of Science. The inaugural issue was released in 2013, and in 2020, we published the 1000th paper in this journal. In 2021, we achieved our goal of publishing 1200 papers in one year. Vaccines is definitely a rapidly developing journal.

In recognition of this significant milestone, we are launching a Special Issue entitled “The 10th Anniversary of Vaccines — Cancer Vaccines and Immunotherapy’. This Special Issue will include high-quality papers on topics within the broad scope of Vaccines. We will consider manuscripts that investigate immunology and vaccinology against cancer. It is our pleasure to invite you to contribute an original research paper or a comprehensive review article for peer review and possible publication in Vaccines.

Dr. Subbaya Subramanian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 44333 KiB  
Article
Cell Surface Fibroblast Activation Protein-2 (Fap2) of Fusobacterium nucleatum as a Vaccine Candidate for Therapeutic Intervention of Human Colorectal Cancer: An Immunoinformatics Approach
by Somrita Padma, Ritwik Patra, Parth Sarthi Sen Gupta, Saroj Kumar Panda, Malay Kumar Rana and Suprabhat Mukherjee
Vaccines 2023, 11(3), 525; https://doi.org/10.3390/vaccines11030525 - 23 Feb 2023
Cited by 15 | Viewed by 2795
Abstract
Colorectal cancer (CRC) is one of the most common cancers and is the second-highest in cancer-related deaths worldwide. The changes in gut homeostasis and microbial dysbiosis lead to the initiation of the tumorigenesis process. Several pathogenic gram-negative bacteria including Fusobacterium nucleatum are the [...] Read more.
Colorectal cancer (CRC) is one of the most common cancers and is the second-highest in cancer-related deaths worldwide. The changes in gut homeostasis and microbial dysbiosis lead to the initiation of the tumorigenesis process. Several pathogenic gram-negative bacteria including Fusobacterium nucleatum are the principal contributors to the induction and pathogenesis of CRC. Thus, inhibiting the growth and survival of these pathogens can be a useful intervention strategy. Fibroblast activation protein-2 (Fap2) is an essential membrane protein of F. nucleatum that promotes the adherence of the bacterium to the colon cells, recruitment of immune cells, and induction of tumorigenesis. The present study depicts the design of an in silico vaccine candidate comprising the B-cell and T-cell epitopes of Fap2 for improving cell-mediated and humoral immune responses against CRC. Notably, this vaccine participates in significant protein–protein interactions with human Toll-like receptors, especially with TLR6 reveals, which is most likely to be correlated with its efficacy in eliciting potential immune responses. The immunogenic trait of the designed vaccine was verified by immune simulation approach. The cDNA of the vaccine construct was cloned in silico within the expression vector pET30ax for protein expression. Collectively, the proposed vaccine construct may serve as a promising therapeutic in intervening F. nucleatum-induced human CRC. Full article
(This article belongs to the Special Issue The 10th Anniversary of Vaccines—Cancer Vaccines and Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1745 KiB  
Review
Antibody Diversity in Cancer: Translational Implications and Beyond
by Raghuram Reddy, Joel Mintz, Roei Golan, Fakiha Firdaus, Roxana Ponce, Derek Van Booven, Aysswarya Manoharan, Isabelle Issa, Bonnie B. Blomberg and Himanshu Arora
Vaccines 2022, 10(8), 1165; https://doi.org/10.3390/vaccines10081165 - 22 Jul 2022
Cited by 2 | Viewed by 2622
Abstract
Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody [...] Read more.
Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the surveillance of serum proteins in cancer patients is relatively challenging because they often show variability in expression and are less abundant. Moreover, an antibody’s presence is also useful as it suggests the relative immunogenicity of a given antigen. For these reasons, profiling antibodies’ responses is actively considered to detect the spread of antigens following immunotherapy. The current review focuses on expanding the knowledge of antibodies and their diversity, and the impact of antibody diversity on cancer regression and progression. Full article
(This article belongs to the Special Issue The 10th Anniversary of Vaccines—Cancer Vaccines and Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop